ICL Delivers Best Operating Income in Three Years, Launches Sweeping Restructuring and $350M+ Cost Plan
ICL is trading near its 52-week low of $4.76 (14% above the low).
Summary
ICL reported Q2 2026 sales of $2.1B and adjusted EBITDA of $448M, its best operating income quarter in three years. The company also announced a divisional reorganization and a >$350M cost savings program, while reaffirming full-year guidance.
Updates
· SEC 6-K — The investor presentation details the new division structure with FY'25 pro forma sales: Essential Minerals $3,046M, Nutrition Solutions $2,063M, Growing Solutions $1,860M, Industrial Products $753M. Cost savings sources: productivity 50-60%, external spend 30-40%, SG&A 10-20%.
Key Events · Earnings and Guidance · ICL
-
Q2 2026 Earnings Beat
Sales rose 17% year-over-year to $2.1B, while adjusted EBITDA of $448M was up nearly $100M. Adjusted diluted EPS of $0.12 beat the prior year's $0.09 by 33%.
-
Major Divisional Reorganization
Effective January 1, 2027, ICL will realign into four divisions—Nutrition Solutions, Industrial Products, Growing Solutions, and Essential Minerals—to better focus on growth engines and improve transparency.
-
Elevate Cost Savings Program
Targeting more than $350M in annualized savings by the end of 2028, the program is expected to deliver significant benefits early in 2027. Implementation began in Q3 2026.
-
Full-Year Guidance Reaffirmed
The company reiterated its 2026 adjusted EBITDA guidance of $1.5B–$1.7B and potash sales volume guidance of 4.5–4.7 million metric tons.
Analysis · ICL · Industrial Applications And Services
The quarter marked ICL's strongest operating income in three years, with sales climbing 17% and adjusted EBITDA jumping nearly $100M to $448M. To sharpen strategic focus and improve investor visibility, the company announced a sweeping reorganization into four end-market-focused divisions, effective January 2027. A new enterprise-wide cost program, Elevate, targets more than $350M in annualized savings by the end of 2028, with significant benefits expected early in 2027. Despite geopolitical headwinds, full-year adjusted EBITDA guidance was reiterated at $1.5B–$1.7B, underscoring management's confidence. Together, the robust results, structural overhaul, and aggressive cost targets mark a pivotal moment for the $6.6B specialty minerals leader.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ICL was trading at $5.42 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $4.76 to $6.97. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.